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Abstract  
Cytokines are signalling molecules, which play an important role in both immune system function and 
brain development and function, and subsequently mental states and behaviour. Cytokines have been 
implicated in eating disorders (EDs) due to their role in psychological health, body weight and 
appetite regulation. This meta-analysis examined cross-sectional and longitudinal studies measuring 
concentrations of cytokines in individuals with EDs. Using PRISMA guidelines, we systematically 
reviewed relevant articles in PubMed, Web of Science, and MEDLINE. Random-effects meta-
analyses were conducted for interleukin (IL)-1β, IL-6, transforming growth factor (TGF)-β, and tumor 
necrosis factor (TNF)-α, independently, firstly with all EDs combined and then stratified by ED 
diagnosis. Twenty-five studies were included: serum/plasma cytokine concentrations were measured 
in people with anorexia nervosa (AN) in 23 studies and bulimia nervosa (BN) in 4 studies. TNF-α and 
IL-6 were elevated in ED participants compared to healthy controls (HCs). Specifically, this pattern 
was seen only when comparing AN participants to HCs. Concentrations of these cytokines did not 
differ between people with BN and HCs. IL-1β and TGF-β did not differ between HCs and any ED 
group. Therefore, AN seems to be associated with elevated concentrations of TNF-α and IL-6. 
Considering the role of cytokines in appetite, mood regulation, and anxiety, these pro-inflammatory 
cytokines could be a potential future drug target helping people with AN, not only with weight gain, 
but also with various coexisting psychological problems. Future studies should consider confounding 
factors that affect cytokine concentrations and report ED-relevant clinical characteristics.  
 
Keywords: eating disorders, cytokines, anorexia nervosa, bulimia nervosa, inflammation 
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1. Introduction  
Eating disorders (EDs) are serious mental illnesses characterised by pathological eating and weight 
control behaviours, and body image disturbances. More specifically, anorexia nervosa (AN) involves 
food restriction and weight-control behaviours resulting in severe weight loss. Both bulimia nervosa 
(BN) and binge eating disorder (BED) are characterised by frequent bingeing, with BN also involving 
inappropriate compensatory behaviours, which are not seen in those with BED (American Psychiatric 
Association, 2013). It is estimated that approximately 20 million people within the European Union 
have an ED (Schmidt et al., 2016). However, the current available treatments for EDs are limited. For 
example, with respect to psychopharmacological treatment options, medications are limited to 
fluoxetine for BN and lisdexamfetamine for BED, which are only approved in certain countries 
(Himmerich and Treasure, 2018). Ultimately, just over half of individuals with BN and AN treated in 
specialist ED services make a full recovery (Smink et al., 2013; Steinhausen, 2002; Steinhausen and 
Weber, 2009), underscoring the need for a greater understanding of ED pathophysiology and for 
novel alternative treatment strategies. 
 
Genetic, neurobiological, gastrointestinal, neuroendocrinological and immunological mechanisms 
have been implicated in the development and maintenance of EDs (Klein and Walsh, 2004; 
Slotwinska and Slotwinski, 2017). An immunological component, strongly interrelated to both the 
neuroendocrine and nervous systems, are cytokines. Cytokines have been shown to be altered in 
people with EDs compared to healthy individuals (Corcos et al., 2003), and are of particular current 
interest in EDs as genome wide association studies have identified significant genome-wide loci 
associated with AN that are closely linked with immune functioning and cytokine signalling (Duncan 
et al., 2017). Cytokines play a role as soluble intercellular signalling proteins with particular 
importance in the immune system. They are produced by a range of cells, including microglia and 
astrocytes, in both the brain and in the periphery (Lichtblau et al., 2013). There is no firm and 
generally accepted categorisation of cytokines (Cavaillon, 2001). However, functionally relevant 
groupings can be used: for example, pro-inflammatory cytokines e.g., tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β) & IL-6; anti-inflammatory cytokines e.g., IL-10; and chemokines e.g., CXC 
chemokine ligand (Zhang and An, 2007).  
 
Cytokines produced in the body’s periphery can access the brain via humoral, neural and cellular 
pathways (see Capuron and Miller, 2011, for a review) and thus, have an effect on mental state, 
including learning, memory, affect, and behaviour through several pathophysiological mechanisms 
(Kelley et al., 2003; Yirmiya and Goshen, 2011). These mechanisms include an influence on the 
metabolism and signal transduction of neurotransmitters, modulation of neuroendocrine systems such 
as the hypothalamus-pituitary-adrenal (HPA) axis, induction of the release of hormones involved in 
feeding and appetite, and an impact on neural plasticity and neurogenesis (Capuron and Miller, 2011; 
Wong and Pinkney, 2004). Alterations in these biological systems may be particularly pertinent given 
that some of these have been linked to the pathophysiology of EDs (Klein and Walsh, 2004).  
 
In recent years, evidence has shown that cytokines play an important role in mental health and the 
pathophysiology of mental disorders, including disorders which are highly comorbid with EDs such 
as depression (Dowlati et al., 2010; Lichtblau et al., 2013), anxiety disorders (Baldwin et al., 2017; 
Quagliato and Nardi, 2017), post-traumatic stress disorder (Hussein et al., 2017; Waheed et al., 2018), 
and sleep disorders (Weschenfelder et al., 2012). Cytokines have also been linked with body weight 
and its regulation (Fonseka et al., 2016); for example, plasma levels of pro-inflammatory cytokine IL-
6 have been shown to correlate positively with body mass index (BMI) (Himmerich et al., 2006; 
Schmidt et al., 2015). Additionally, cytokines are involved in the regulation of food intake 
(Himmerich and Sheldrick, 2010) and appetite (Andréasson et al., 2007; Dent et al., 2012), which may 
be due to interactions with orexigenic and anorexigenic signals (Wong and Pinkney, 2004). Given the 
involvement of cytokines in psychological health, weight, and regulation of feeding behaviour and 
appetite, this provides a rationale for considering the role of cytokines in EDs.  
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Over the past two decades, several reviews have considered the role of cytokines in EDs (Brown et 
al., 2008; Corcos et al., 2003; Holden and Pakula, 1996; Marcos, 1997; Slotwinska and Slotwinski, 
2017). More recently, a meta-analysis has shown circulating concentrations of pro-inflammatory 
cytokines TNF-α, IL-1β & IL-6 to be elevated in people with AN, in comparison to healthy controls 
(HCs) and the concentration of these cytokines did not change with weight gain (Solmi et al., 2015). 
However, research in other EDs is mixed (Corcos et al., 2003) and has not been recently 
systematically collated. Therefore, the aim of this meta-analysis was to synthesise studies 
investigating cytokine concentrations in individuals with EDs, both in comparison to healthy 
individuals and longitudinally, and to update the previously described meta-analysis on cytokines in 
AN (Solmi et al., 2015). In line with this, the key research questions were: (i) do cytokine 
concentrations differ between people diagnosed with an ED and healthy individuals; and (ii) in ED 
participants, do cytokine concentrations change as a function of weight gain and/or symptom 
improvement? 
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2. Material and methods  
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). We used the Newcastle-Ottowa Scale 
(NOS) (Wells et al., 2015) adapted for cross-sectional studies (see Supplementary File 1) to determine 
the quality of included studies. The NOS is a widely used quality assessment tool for non-randomised 
studies of multiple designs. 
2.1. Literature search 
Three electronic databases (PubMed, ISI Web of Science Core Collection, and MEDLINE via Ovid 
SP) were searched from inception until 4th May 2018, using the following keywords, which were 
mapped to Medical Subject Headings with the Explode function where possible: eating disorder*, 
anorexia nervosa, bulimi*, binge eat* in combination with cytokine*, chemokine*, inflammat*, 
interleukin, interferon, IFN, tumor necrosis factor, TNF, transforming growth factor, TGF. These 
searches were supplemented by internet searches, hand-searches of reference lists of potentially 
relevant papers and reviews, and citation tracking in Google Scholar.  
2.2. Inclusion/exclusion criteria  
Studies in any language of any study design that assessed cytokine concentrations in the serum, 
plasma or cerebrospinal fluid (CSF) of individuals with a Diagnostic and Statistical Manual of Mental 
Disorders (DSM) (American Psychiatric Association, 1980; American Psychiatric Association, 2000; 
American Psychiatric Association, 2013) or International Statistical Classification of Diseases (ICD) 
(World Health Organization, 1992) diagnosis of an ED were eligible for inclusion. Publications were 
included if they reported cross-sectional comparisons of cytokine concentrations between ED groups 
and HCs or longitudinal assessments. Longitudinal studies were included if cytokine concentrations 
were measured at a minimum of two time-points, and BMI or ED symptoms were also assessed at 
both time points. 
Studies were excluded if: i) they did not report group comparisons or longitudinal measurements of 
cytokine concentrations; ii) participants had an organic cause for their disordered eating e.g., cancer, 
immunological conditions, genetic disorder, etc.; iii) the sample was comprised of animals; or iv) they 
measured cytokine production or genetic expression but did not assess cytokine concentrations. 
Review articles, meta-analyses, conference proceedings/abstracts, book chapters, and unpublished 
theses were also not included. 
2.3. Search selection 
Titles and abstracts of retrieved publications were imported into EndNote. Duplicates were removed, 
and papers deemed highly unlikely to be relevant were disregarded. Full-text versions of the 
remaining articles were then obtained and screened according to the pre-specified eligibility criteria 
described above. All papers that did not meet the inclusion criteria were excluded, with the reasons 
documented (see Figure 1). The entire search process was conducted independently by two reviewers 
(B.D. and S.B.) and disagreements at the final stage were resolved by consensus.  
2.4. Data extraction  
The principal reviewer (B.D.) extracted data from all included studies into an electronic summary 
table, which was then checked by another reviewer (S.B.). Information collected related to: i) sample 
characteristics, including sample size, demographics, diagnostic criteria and clinical characteristics 
(e.g. illness duration, BMI), and medication status; and ii) parameters of interest, measurement 
methods, and concentrations of cytokines. Authors were contacted if the required data were not 
available in the publication. 
2.5. Summary measure 
The principle outcome measure was cytokine concentrations (pg/ml or ng/ml). 
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2.6. Synthesis of data 
Individual meta-analyses were performed for each cytokine (with 2 or more available studies; The 
Cochrane Collaboration, 2011) for all EDs combined and then for each ED separately. For studies that 
included more than one diagnostic group (e.g. AN and BN participants) or AN subtype, the means and 
standard deviations for each group were pooled for the combined EDs and/or AN meta-analyses. 
Reported standard error means were converted to SDs. The required data were not available to 
conduct meta-analyses on longitudinal measurements of cytokines, controlling for within-subject 
correlations. 
 
2.7. Statistical analysis 
All meta-analyses were conducted in Stata/SE 15.0 (StataCorp, 2017) using the ‘metan’ command. 
The standardised mean difference (SMD) was used as the summary statistic, which expresses the size 
of the effect in each study (EDs vs. HCs) relative to the variability observed in that study. SMD is 
used in meta-analyses when included studies assess the same outcome but measure it in a variety of 
ways and therefore it is necessary to standardise the results of the studies before they are combined 
(The Cochrane Collaboration, 2011). For all meta-analyses, a random effects model was specified 
using the DerSimonian & Laird method (DerSimonian and Laird, 1986) and SMDs were pooled using 
Hedges method (Hedges, 1981). The random effects model assumes both within-group variability and 
between-study heterogeneity. Positive SMDs were indicative of higher cytokine concentrations in the 
ED compared to the HC participants. A p-value <0.05 indicated a significant difference between the 
ED and HC groups.  
 
Between study heterogeneity was assessed by calculating Higgins I2 (Higgins et al., 2003) based on 
Cochran’s Q indexes. I2 measures the percentage of total variation across studies due to heterogeneity. 
Moderate (50%) to high (75% to 100%) heterogeneity was suspected between studies, and for this 
reason a random effects meta-analysis was used in all cases (Higgins et al., 2003). Significant 
between-study heterogeneity was further explored using sub-group analyses and/or meta-regressions 
using the STATA ‘metareg’ command. The meta-regressions investigated the effect of age, BMI and 
illness duration on the SMD in cytokines between ED and HC groups. Subgroup analyses of the AN 
meta-analyses were stratified by AN subtype (restrictive [AN-R] or binge-purge [AN-BP]). 
 
Publication bias was assessed using the Duval and Tweedie trim and fill method (Duval and Tweedie, 
2000), which identifies and adjusts for funnel plot asymmetry, and Eggers test (Egger et al., 1997) for 
small study effects.  
 
INSERT FIGURE 1 HERE  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
3. Results 
3.1. Characteristics of included studies and participants 
We identified 25 studies (ED n=632, HC n=487), conducted in 9 countries, which met the inclusion 
criteria for a quantitative analysis and for which the required data were available (see Figure 1 for 
PRISMA flow diagram). Study and sample characteristics are presented in Table 1. Two studies 
included multiple ED subgroups (Ahrén-Moonga et al., 2011; Brambilla et al., 1998). Twenty-three 
studies reported cross-sectional comparisons in cytokine concentration between participants with AN 
(n=538) and HCs, identifying four new studies not included in the previous meta-analysis (Solmi et 
al., 2015). Within these, 12 reported sub-type information: all assessed cytokine concentrations in 
participants with AN-R and 3 studies additionally reported on participants with AN-BP separately. 
Four studies compared cytokine concentrations in BN participants (n=75) to HCs. No studies assessed 
cytokine concentrations in patients with BED or other EDs.  
The mean age of participants (reported in n=19 studies) with EDs and HCs was 21.39 ± 4.10 and 
22.62 ± 5.18, respectively. All studies only included female participants. The mean BMI (reported in 
n=20 studies) of ED participants was 15.63 ± 1.83 kg/m2 (AN participants, n=19 studies: 15.15 ± 1.17 
kg/m2, BN participants, n=2 studies: 21.25 ± 2.19 kg/m2) and of HCs was 21.32 ± 1.98 kg/m2, 
respectively. Mean illness duration for ED participants, reported in 8 studies, was 3.66 ± 2.59 years. 
ED diagnosis was based on the DSM-IV (n=24) (American Psychiatric Association, 2000) or the 
DSM-III (n=1) (American Psychiatric Association, 1980). Medication usage of ED participants was 
reported in 14 studies, of which participants in 11 studies were confirmed medication-free at 
assessment (Allende et al., 1998; Brambilla et al., 1998; Brambilla et al., 2001; Dolezalova et al., 
2007; Karczewska-Kupczewska et al., 2013; Karczewska-Kupczewska et al., 2012; Nagata et al., 
2006; Nakai et al., 1999; Nakai et al., 2000; Pomeroy et al., 1994; Shimizu et al., 2005). In two 
studies (Ahrén-Moonga et al., 2011; Nogueira et al., 2010), n=26 were reported to be taking 
antidepressants, neuroleptics, anxiolytics and/or sedatives, and in the remaining study, participants 
were not taking medication known to affect nutritional or bone status (Ostrowska et al., 2016). 
Cytokines included in the meta-analyses were IL-1β, IL-6, TGF-β and TNF-α. Other cytokines (IFN-
γ, IL-1, IL-2, Il-4, IL-5, IL-7, IL-10, macrophage inhibitory cytokine-1) were also measured in 
eligible studies, however, the data were not available for two or more studies and could not be 
included in a meta-analysis. Seventeen studies measured cytokine concentrations in serum, 8 in 
plasma and none in CSF. Measurement methods included immuno-assays (22 studies: enzyme 
immune-assay n=18, radio immune-assay n=2, undefined n=2) or bioassay (1 study). The remaining 
studies did not provide sufficient information to classify their measurement methods. 
The quality ratings for each study are presented in Supplementary File 1. Few studies ensured 
representativeness of sample through their sampling method (n=6) or provided justification for their 
sample size (n=1). Most studies accounted for age as a confounding factor (n=21), however, the 
majority of studies did not control for additional important confounding factors (e.g., smoking and 
BMI). Thirteen studies used a validated method to measure outcome, with the remaining studies using 
a non-validated measurement method that was described in sufficient detail. In all studies, the 
statistical test used was clearly described and appropriate.  
 
  INSERT TABLE 1 HERE 
 
3.2. Meta-analysis results 
Results are summarised in Table 2 and forest plots not presented here can be seen in Supplementary 
File 2. 
3.2.1. Across all EDs 
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Pro-inflammatory cytokines. IL-1β was measured in 7 studies including 205 ED participants and 102 
HCs (Allende et al., 1998; Brambilla et al., 1998; Brambilla et al., 2001; Nogueira et al., 2010; 
Ostrowska et al., 2015; Vaisman et al., 2004; Yasuhara et al., 2007). The concentration of IL-1β did 
not differ between groups (SMD=0.77; 95% CI -0.13, 1.66; p=0.093).  
Thirteen studies measured IL-6 (Ahrén-Moonga et al., 2011; Brambilla et al., 1998; Brambilla et al., 
2001; Corcos et al., 2001; Dolezalova et al., 2007; Karczewska-Kupczewska et al., 2013; Misra et al., 
2006; Nagata et al., 2006; Ostrowska et al., 2015; Pomeroy et al., 1994; Terra et al., 2013; Víctor et 
al., 2015; Yasuhara et al., 2007) and found concentrations of IL-6 to be significantly higher in 
participants with EDs (n=331) than HCs (n=258) (SMD=0.53; 95% CI 0.19, 0.87; p=0.002).  
Across 18 studies (Agnello et al., 2012; Ahrén-Moonga et al., 2011; Allende et al., 1998; Brambilla et 
al., 1998; Brambilla et al., 2001; Corcos et al., 2001; Jiskra et al., 2000; Karczewska-Kupczewska et 
al., 2012; Krizova et al., 2008; Krizova et al., 2002; Nakai et al., 1999; Nakai et al., 2000; Nogueira et 
al., 2010; Ostrowska et al., 2015; Shimizu et al., 2005; Vaisman et al., 2004; Víctor et al., 2015; 
Yasuhara et al., 2007), there were significantly higher concentrations of TNF-α in ED participants 
(n=454) compared to HCs (n=344) (SMD=0.56; 95% CI 0.17, 0.94; p=0.005).  
Other cytokines. Three studies that measured TGF-β (Corcos et al., 2001; Ostrowska et al., 2016; 
Pomeroy et al., 1994) suggested lower concentrations in ED participants (n=105; consists of 
exclusively AN participants) compared to HCs (n=51), though this difference did not reach statistical 
significance (SMD=-0.59; 95% CI -2.37, 1.20; p=0.518). 
3.2.2. Anorexia nervosa 
Pro-inflammatory cytokines. IL-1β measurements were made in 162 AN participants and 102 HCs 
from 7 studies (Allende et al., 1998; Brambilla et al., 1998; Brambilla et al., 2001; Nogueira et al., 
2010; Ostrowska et al., 2015; Vaisman et al., 2004; Yasuhara et al., 2007), extending the previous 
meta-analysis (Solmi et al., 2015) by 3 studies (additional 77 AN participants and 35 HCs). Between-
group differences in IL-1β did not reach statistical significance in AN (SMD=0.78; 95% CI -0.17, 
1.72; p=0.110), nor in subgroup analyses of AN-BP participants (SMD=1.13; 95% CI -0.30, 2.57; 
p=0.122) (Brambilla et al., 1998; Brambilla et al., 2001; Nogueira et al., 2010). Participants with AN-
R showed significantly higher levels of IL-1β than HCs (SMD=0.49; 95% CI 0.08, 0.89; p=0.018) 
(Brambilla et al., 1998; Brambilla et al., 2001; Nogueira et al., 2010; Yasuhara et al., 2007). 
Measurements of IL-6 were extracted from 12 studies, consisting of 276 AN participants and 244 HCs 
(Ahrén-Moonga et al., 2011; Brambilla et al., 1998; Brambilla et al., 2001; Corcos et al., 2001; 
Dolezalova et al., 2007; Karczewska-Kupczewska et al., 2013; Misra et al., 2006; Ostrowska et al., 
2015; Pomeroy et al., 1994; Terra et al., 2013; Víctor et al., 2015; Yasuhara et al., 2007); including an 
additional 94 AN and 64 HC participants (from 3 extra studies) compared to Solmi et al. (2015). 
There were significantly higher concentrations of IL-6 in AN participants compared to HCs 
(SMD=0.59; 95% CI 0.24, 0.94; p=0.001) (see Figure 2). Subgroup analyses found a trend towards 
higher levels of IL-6 in AN-R compared to HC participants, but this difference did not reach statistical 
significance (SMD=0.36; 95% CI -0.07, 0.78; p=0.105) (Brambilla et al., 1998; Brambilla et al., 
2001; Karczewska-Kupczewska et al., 2013; Misra et al., 2006; Terra et al., 2013; Yasuhara et al., 
2007).  
 
INSERT FIGURE 2 HERE 
Across 17 studies (Agnello et al., 2012; Ahrén-Moonga et al., 2011; Allende et al., 1998; Brambilla et 
al., 1998; Brambilla et al., 2001; Corcos et al., 2001; Jiskra et al., 2000; Karczewska-Kupczewska et 
al., 2012; Krizova et al., 2008; Krizova et al., 2002; Nakai et al., 1999; Nogueira et al., 2010; 
Ostrowska et al., 2015; Shimizu et al., 2005; Vaisman et al., 2004; Víctor et al., 2015; Yasuhara et al., 
2007), TNF-α concentrations were significantly higher in AN participants (n=380) compared to HCs 
(n=324) (SMD=0.48; 95% CI 0.09, 0.87; p=0.015) (see Figure 3). This expands the sample of the 
previous meta-analysis (Solmi et al., 2015) by 145 AN participants and 106 HCs from 6 additional 
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studies. Subgroup analyses showed that between-group differences for AN-R (Brambilla et al., 1998; 
Brambilla et al., 2001; Jiskra et al., 2000; Karczewska-Kupczewska et al., 2012; Krizova et al., 2002; 
Nogueira et al., 2010; Shimizu et al., 2005; Yasuhara et al., 2007) and AN-BP (Brambilla et al., 1998; 
Brambilla et al., 2001; Nogueira et al., 2010) compared to HCs did not reach statistical significance 
(AN-R: SMD=0.12; 95% CI -0.20, 0.44; p=0.470; AN-BP: SMD=-0.50; 95% CI -1.31, 0.30; 
p=0.221).  
 
INSERT FIGURE 3 HERE 
 
Other cytokines. See analysis for TGF-β in Section 3.3.1. This analysis included a recent study 
(Ostrowska et al., 2016) unavailable for the previous meta-analysis (Solmi et al., 2015), which 
increased the AN sample by 60 participants. 
3.2.3. Bulimia Nervosa 
Pro-inflammatory cytokines. IL-6 concentrations were measured in 55 participants with BN and 52 
HCs, taken from 3 studies (Ahrén-Moonga et al., 2011; Brambilla et al., 1998; Nagata et al., 2006). 
Between-group differences did not reach statistical significance (SMD=0.13; 95% CI -0.49, 0.76; 
p=0.67).  
Concentrations of TNF-α were extracted from 3 studies (Ahrén-Moonga et al., 2011; Brambilla et al., 
1998; Nakai et al., 2000), suggesting higher concentrations of TNF-α concentrations in BN 
participants (n=55) compared to HCs (n=58); however, this did not reach statistical significance 
(SMD=0.90; 95% CI -0.26, 2.06; p=0.13).  
 
INSERT TABLE 2 HERE 
 
3.2.4. Meta-regressions 
The results of the meta-regressions are presented in Table 3. Age significantly contributed to the 
SMDs for IL-6 for the combined ED group and AN group, which may account for some of the 
observed heterogeneity. The remaining results were non-significant and BMI did not significantly 
contribute to the SMDs in any group. 
Some meta-regressions were limited by the number of studies that could be included, particularly in 
relation to IL-1β, as only 6 studies were available. This violates the recommended guidelines of a 
requirement of 10 studies for a meta-regression (The Cochrane Collaboration, 2011). For this reason, 
illness duration could not be included in the meta-regressions as this limited the number of studies to 
n=5. 
 
INSERT TABLE 3 HERE 
 
3.2.5. Sensitivity analyses 
Moderate to high heterogeneity (>50%) was observed in all meta-analyses conducted (except for AN-
R IL-1β and TNF-α), as seen in Table 2. According to Egger’s test for small study effects, there is 
presumed to be no publication bias, as all analyses were non-significant. The trim and fill method 
showed that there were missing studies in the analysis of TNF-α concentrations in BN and TGF-β in 
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AN. When the SMDs were re-estimated after adjusting for missing studies, they remained non-
significant. All other analyses showed no evidence of missing data using the trim and fill method. 
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4. Discussion 
4.1. Summary of findings 
This is the first meta-analysis to investigate cytokine concentrations across all EDs. AN was most 
researched (n=23 studies), followed by fewer investigations of cytokine concentrations in BN (n=4 
studies). No studies reported on cytokine concentrations in BED or other EDs. The only available 
cytokines to be included in meta-analyses were TNF-α, IL-6, IL-1β, and TGF-β. Generally, studies 
reported on a limited number of cytokines and several important cytokines are yet to be measured in 
ED samples; e.g., IL-17 is a key cytokine for immune response and seems to play a role in the 
development of other psychiatric disorders and their treatment (Borovcanin et al., 2012; Davami et al., 
2016; Himmerich et al., 2011). This highlights the need for future studies to assess a broad range of 
cytokines. Moderate to high heterogeneity in most analyses may be accounted for by methodological 
issues, as discussed below (Section 4.4). The required data were not available to assess changes in 
cytokine concentrations longitudinally therefore, we were unable to investigate our second research 
question. 
In whole-group analyses for EDs, both TNF-α and IL-6 concentrations were found to be elevated in 
comparison to HCs. In sub-group analyses, these differences were observed in the AN, but not in the 
BN group, suggesting that the findings in the combined ED group, may have been driven by the 
elevation in AN participants. Results in AN participants replicate those identified in the previous 
meta-analysis (Solmi et al., 2015). Both TNF-α and IL-6 are classed as pro-inflammatory cytokines 
involved in the acute-phase response and are secreted into the blood stream in response to an 
immunological challenge. TNF-α is produced by macrophages, natural killer cells and T cells and 
stimulates the release of other pro-inflammatory cytokines and neutrophils, and induces fever (Abbas 
et al., 2014). IL-6 is produced by macrophages, endothelial cells and T cells, and is involved in the 
proliferation of antibody-producing cells (Abbas et al., 2014). 
Similar to the findings in Solmi et al. (2015), TGF-β, a multi-functional transforming growth factor, 
was not found to differ between ED and HC participants. However, this analysis was limited to three 
studies in AN participants and therefore it is premature to draw conclusions from these data. In 
addition, IL-1β, a pro-inflammatory acute-phase response protein, did not differ between ED, AN or 
BN participants and HCs. Including three additional studies in the current meta-analysis did not 
replicate the findings from the previous meta-analysis (Solmi et al., 2015), which found elevated 
levels of IL-1β in AN compared to HCs. However, in subgroup analyses, IL-1β was found to be 
elevated in participants with AN-R, but not AN-BP, compared to HCs, as seen in Solmi et al. (2015). 
The significant findings limited to this restrictive subgroup may make sense given that IL-1β is 
anorexigenic and findings from animal studies have implicated IL-1β in reduced food intake: more 
specifically, administration of IL-1β results in reduced meal size and meal duration, but not meal 
frequency, and reduced food-seeking behaviour (Plata-Salaman, 2001; Wong and Pinkney, 2004). 
Meta-regressions suggest that age may have contributed to the SMDs observed for IL-6 for both the 
combined ED and AN groups. Variations in age may therefore account for some of the observed 
heterogeneity, highlighting the importance of including a range of ages in investigations of cytokine 
concentrations in EDs. When included as a covariate, BMI did not appear to be a major factor 
influencing cytokine concentrations in people with EDs. In line with this, when BMI was used as a 
covariate in an included study, significantly elevated levels of TNF-α and IL-6 were still observed in 
AN participants compared to HCs (Víctor et al., 2015). 
4.2. Mechanisms of effect 
There are several mechanisms that may account for the elevated pro-inflammatory cytokines observed 
in those with EDs compared to HCs. Two such factors will be briefly discussed: stress, and the gut 
microbiota.  
Firstly, stress can induce the release of and increase production of pro-inflammatory cytokines 
(Ménard et al., 2017). This elevation has been found in a number of animal studies in which hyper-
production of cytokines was induced by acute and chronic stress paradigms (Himmerich et al., 2013; 
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Krügel et al., 2014; Liu et al., 2012). The mechanism as to how stress leads to an increase of pro-
inflammatory cytokine production remains unclear. Importantly, psychological stress has been shown 
to augment the production of cytokines in humans (Glaser and Kiecolt-Glaser, 2005; Steptoe et al., 
2007). Therefore, the presence of depression and/or anxiety, which are both highly comorbid with 
EDs, may play a role in the observed elevated concentrations of TNF-α and IL-6 (Dowlati et al., 2010; 
Felger and Lotrich, 2013; Furtado and Katzman, 2015; Kim and Won, 2017). Few studies assessed 
levels of stress, depression or anxiety and therefore, this cannot be determined. 
Secondly, bacteria from the gut microbiota can stimulate the production of cytokines. This occurs 
when bacterial determinants, e.g., the lipopolysaccharide (LPS) component of the bacteria’s cell 
walls, bind to pattern recognition receptors, e.g., Toll-like receptor 4, on circulating monocytes and 
macrophages (Sherwin et al., 2016) and gut epithelial cells. It is likely that dysregulation of intestinal 
microbiota is associated with EDs, given that the profile of gut microbiota is determined by the host’s 
diet and EDs are characterised by dysregulated food intake (Lam et al., 2017). Furthermore, in AN, 
starvation is thought to provoke a ‘leaky gut’ in which the intestinal epithelial barrier is broken down 
(Herpertz-Dahlmann et al., 2017). This leads to ‘leaking’ of bacteria and/or their components from the 
gut into circulation which is then thought to elicit an inflammatory response i.e. stimulating cytokine 
production (Herpertz-Dahlmann et al., 2017; Sherwin et al., 2016). Little research has considered the 
role of gut microbiota in BN or BED. However, gut microbiota and regulation of the "gut-brain axis" 
have been proposed to play a significant role in stress and other psychiatric disorders that are highly 
comorbid with BN and BED, such as depression and anxiety, via their influence on inflammatory 
cytokines. This suggests such factors could contribute to alterations in cytokine production in these 
EDs (Alam et al., 2017; Kelly et al., 2015). 
Once cytokine alterations have occurred through these and/or other mechanisms, cytokines can affect 
brain function and development, and subsequently mental states and behaviour, through their 
influence on several systems (Capuron and Miller, 2011; Wong and Pinkney, 2004). Cytokines can 
influence the synthesis, release, and reuptake of relevant neurotransmitters, such as serotonin and 
dopamine (Felger and Lotrich, 2013). For example, cytokines have been shown to influence the 
synthesis of neurotransmitters by stimulating the production of Indoleamine 2,3 dioxygenase, which 
breaks down tryptophan, an essential amino acid. This depletion of tryptophan is thought to contribute 
to a reduced availability of serotonin (Capuron and Miller, 2011; Miller et al., 2009). In addition, pro-
inflammatory cytokines have been shown to disrupt tetrahydrobiopterin (BH4), which is an enzyme 
that is an essential cofactor for enzymes involved in the synthesis of monoamine neurotransmitters, 
including dopamine and serotonin (Haroon et al., 2012; Miller et al., 2013). This may be particularly 
pertinent, given that dysregulated serotonin and dopamine have been implicated in EDs (Broft et al., 
2011; Gauthier et al., 2014; Kaye et al., 2005; O'Hara et al., 2015). Furthermore, the direct action of 
cytokines on the brain can influence neuroendocrine functioning. For example, cytokine exposure has 
been shown to activate the HPA axis, potentially by inhibiting glucocorticoid receptors (Capuron and 
Miller, 2011; Pace and Miller, 2009). This is of importance given that hyperactivation of the HPA 
axis has been reliably observed in AN, and more mildly in BN patients, in the acute phase of illness 
(Lo Sauro et al., 2008).  
4.3. Clinical implications 
As we identified elevated concentrations of circulating TNF-α and IL-6 levels in people with AN 
compared to HCs, cytokines may represent a potential biomarker of AN. However, as cytokines have 
been found to be elevated in other psychiatric disorders (e.g., Baldwin et al., 2017; Dowlati et al., 
2010; Dunjic-Kostic et al., 2013b; Passos et al., 2015) and inflammatory diseases (e.g., Aaltonen et 
al., 2012), cytokines may not be a specific biomarker for AN but rather a non-specific marker of 
overall illness severity or general treatment response. 
Cytokines such as IL-6 and TNF-α have repeatedly been shown to reduce food intake in animals and 
humans after peripheral and central administration (Langhans and Hrupka, 1999; McCarthy, 2000). 
Therefore, it has been suggested that they contribute to the development of anorexia in various 
infectious, neoplastic and autoimmune diseases. This seems to be due to peripheral anorexigenic 
effects of cytokines, such as an increase in the production of leptin, a hormone produced by the 
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adipose tissues (Finck et al., 1998; Grunfeld et al., 1996; Kirchgessner et al., 1997), but also due to the 
anorectic effects of pro-inflammatory cytokines on appetite-regulating hormones such as histamine, 
alpha-melanocyte stimulating hormone, ghrelin, and neuropeptide Y (Himmerich and Sheldrick, 
2010; Huang et al., 1999; Langhans and Hrupka, 1999; Sahu et al., 1988; Wong and Pinkney, 2004).  
Additionally, as mentioned, pro-inflammatory cytokines have been implicated in the pathophysiology 
of depression (Dowlati et al., 2010; Lichtblau et al., 2013), anxiety (Baldwin et al., 2017), and 
disturbed sleep (Weschenfelder et al., 2012). Patients with AN often do not want medication that 
induce weight gain, although this is necessary from a medical perspective, but rather want help with 
anxiety, low mood and sleep disturbances (Himmerich et al., 2017). Cytokines could theoretically be 
drug targets for the treatment of AN that addresses both the medical necessity for weight gain and 
patients’ priorities of coexisting psychological problems. There is currently very little research 
investigating the therapeutic effect of cytokine blockers in AN (e.g., Barber et al., 2003; Solmi et al., 
2013). However, these biologics have been shown to reduce depressive symptoms in patients with 
inflammatory diseases such as psoriasis (Tyring et al., 2006), and antidepressant-like effects of TNF-α 
blockers have been seen in rats, using a chronic stress model for depression (Krügel et al., 2013). In 
addition, anti-TNF-α medication has been shown to lead to increases in body weight in those with 
chronic inflammatory diseases (Ouchi et al., 2011).  
As seen in the included studies, some ED participants show similar cytokine concentrations to HCs 
(e.g., Agnello et al., 2012). Therefore, it is important to consider that only a subgroup of patients will 
present with an immunological basis to the disorder, displaying elevated cytokine concentrations 
compared to HCs and for these patients, cytokines may be a potential future treatment target 
(Himmerich and Treasure, 2018).  
Taken together, a subgroup of individuals with AN may benefit from treatment targeted on reducing 
pro-inflammatory cytokines such as TNF-α blockers (Berthold-Losleben et al., 2009; Bou Khalil et 
al., 2011), which are readily available for the treatment of inflammatory diseases (e.g., Aaltonen et al., 
2012). However, carefully designed randomised controlled clinical trials will be required to 
investigate the role of cytokines as a treatment target in AN. 
4.4. Methodological considerations  
Several methodological issues, including technical factors and clinical confounders, may contribute to 
the moderate to high heterogeneity observed. Most studies did not account for confounding clinical 
and lifestyle factors that have been shown to affect cytokine production, e.g., age, menstruation, 
smoking status, medication, exercise, body fat, and concurrent diagnoses relating to physical and 
mental health (Dugué et al., 1996; Goebel et al., 2000; Haack et al., 1999; Munzer et al., 2013; Ouchi 
et al., 2011; Rom et al., 2013). Thus, future studies need to consider factors that may influence the 
measurement of cytokine concentrations within their study design and analyses.  
Few studies measured or reported relevant clinical characteristics such as illness duration, age of 
illness onset, or ED symptom severity. Variability in such sample characteristics may contribute to the 
observed heterogeneity. In addition, participants’ treatment status varied and differences associated 
with these, such as the opportunity to engage in ED behaviours (e.g., restrictive eating, purging), may 
impact on cytokine concentrations (e.g., Canavan et al., 2005). Of interest, research in other 
psychiatric disorders has shown that certain clinical characteristics are associated with cytokine levels 
(e.g., Dunjic-Kostic et al., 2013a; Dunjic-Kostic et al., 2013b; Gill et al., 2008). Therefore, future 
studies would benefit from including information on such clinical factors to further determine the role 
of cytokines in EDs.  
With regards to the HC samples, not all studies used a validated measure to systematically screen and 
exclude for current or previous psychiatric disorders in the HCs. This cannot rule out the presence of 
other psychiatric disorders, which as previously cited, have been shown to impact cytokine 
concentrations. Biases such as these in the HC sample may influence the accuracy of the results. 
An additional consideration is that the specific methodologies in each of the laboratories used to 
measure cytokine concentrations is likely to vary considerably between studies, including the 
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equipment used (e.g., immunoassays, bioassays). Different assay procedures may yield different 
results (Zhou et al., 2010) and certain platforms for cytokine assessment are more sensitive than 
others (Malekzadeh et al., 2017). However, use of random effects models accounts for such between-
study heterogeneity. 
4.5. Strengths and limitations 
The primary strength of this meta-analysis was its objectivity and the systematic evaluation of 
cytokine concentrations across multiple EDs, utilising all available research to date in this area. This 
meta-analysis was also conducted and reported in line with the PRISMA guidelines. In addition, a 
number of methodological considerations have been highlighted, which can be incorporated into 
future studies in order to advance our understanding of immunological factors involved in the 
pathophysiology of EDs. We have expanded on the previous meta-analysis of cytokines and AN 
(Solmi et al., 2015) by including all EDs, identifying 4 new studies assessing cytokines in AN 
participants, and also applying additional data from 2 previously included studies (Corcos et al., 2001; 
Vaisman et al., 2004) to provide a more comprehensive analysis. All analyses, except for the 
assessment of TNF-α in BN and TGF-β in AN, showed no evidence of publication bias. 
With regards to limitations, few studies assessed concentrations of TGF-β and also more generally, 
cytokines in BN and AN-BP. It has been suggested that a minimum of 5 studies is required in order to 
achieve reasonable power for a random effects meta-analysis, which is greater than the power from 
the individual studies (Jackson and Turner, 2017). Therefore, the meta-analyses of TGF-β and these 
patient groups may lack power to detect an effect and the current results should be interpreted with 
caution. Furthermore, as associations between binge eating and purging symptoms and TNF-α 
concentrations have been identified (Lofrano-Prado et al., 2011), future studies should aim to expand 
the literature base of cytokines and BN. This also warrants the measurement of cytokine 
concentrations in individuals diagnosed with BED, for which no data are currently available. In 
comparison to Solmi et al. (2015), we limited our research question to cytokines only and did not 
include data on the associated receptors. To provide a more full and complex picture of the cytokine 
network, future reviews should consider the role of cytokine receptors across EDs. 
The predictive capability of the meta-regressions was limited due to missing data on covariates of 
interest (e.g., BMI and illness duration) in several studies. While many longitudinal studies were 
eligible for inclusion, meta-analyses could not be conducted as the data needed to control for within-
group correlations between time points were not available. As inflammatory processes, and in 
particular cytokines, have been suggested as a possible biomarker involved in illness staging and the 
neuroprogression of illness (McGorry et al., 2014), the opportunity to include longitudinal data may 
have provided greater insight into potential biological mechanisms underlying EDs and whether 
cytokine concentrations could be a marker of treatment response.  
4.6. Conclusions and future directions 
Current treatments for people with EDs are limited, and an improved understanding of the underlying 
biology may lead to novel treatment strategies. The current meta-analysis found that participants with 
EDs showed elevated concentrations of circulating TNF-α and IL-6, but not IL-1β or TGF-β, 
compared to HCs. This pattern of results was also observed in AN, but not BN participants when 
analyses were stratified by ED diagnosis. The majority of the meta-analyses showed moderate to high 
heterogeneity, which could be accounted for by various methodological issues, such as limited 
measurement and/or reporting of confounding factors in the measurement of cytokines (e.g., smoking 
status), variability in equipment and methods used to measure cytokines, and heterogeneity in sample 
characteristics.  
Further studies should measure a broad range of cytokines and given that cytokines are part of a 
complex network, they should be analysed in functionally meaningful cytokine groupings. 
Furthermore, future research should consider measuring cytokines in all EDs, including BN and BED, 
and include separate analyses of AN subtypes. This research would also benefit from including 
psychological assessments of ED symptoms alongside cytokine measurement. This will permit further 
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assessment of the role of cytokines in EDs and may provide the basis for investigations into 
immunomodulatory medication as a treatment for EDs. 
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Figure Legends 
Figure 1. PRISMA flow diagram. Abbreviations: DSM = Diagnostic and Statistical Manual of Mental 
Disorders; ICD = International Classification of Diseases. 
Figure 2. Forest plot of standardised mean difference in IL-6 between AN participants and HCs from 
n=12 studies (n=276 AN, n=244 HC). Zero is the line of no effect, and points to the right of zero 
indicate an elevation in IL-6 in AN compared to HCs. IL-6 was found to be significantly higher in AN 
participants than in HCs (p=0.001). Abbreviations: SMD = standardised mean difference; CI = 
confidence intervals. 
Figure 3. Forest plot of standardised mean difference in TNF-α between AN participants and HCs 
from n=17 studies (n=380 AN, n=324 HC). Zero is the line of no effect, and points to the right of zero 
indicate an elevation in TNF-α in AN compared to HCs. TNF-α was shown to be significantly higher 
in AN participants than in HCs (p=0.015). Abbreviations: SMD = standardised mean difference; CI = 
confidence intervals.  
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Table 1. Study and sample characteristics for studies included in the meta-analyses. 
Study/country 
 
Study design Sample N Mean ± 
SD age 
(years) 
Mean ± SD 
BMI 
(kg/m2) 
Mean 
illness 
duration 
(years) 
Diagnostic 
criteria 
ED participants 
medication 
status 
Parameters 
of interest 
Measurement method 
Agnello et al. 
Italy 
2012 Cross-sectional Female AN 
Female HC 
39 
25 
26.0 ± 9.0 
26.0 ± 3.0 
13.9 ± 2 
21.0 ± 2 
NR 
- 
DSM-IV NR TNF-α  
 
Serum - double-
antibody ELISA 
Ahren-
Moonga et 
al. 
Sweden 
2011 Cross-sectional Female ED 
- AN 
- BN 
Female HC 
26 
15 
11 
12 
27.9 ± 8.0 
NR 
NR 
28.2 ± 7.2 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
- 
DSM-IV n=16 
antidepressants 
and/or sedatives 
IL-6, TNF-α Serum - high-
sensitivity 
immunoassay 
Allende et al. 
Spain 
1998 Cross-sectional 
& 
longitudinal 
Female AN 
BMI<17.5 
Female AN 
BMI>17.5 
Female HC 
21 
19 
14 
16.9 ± 2.9 
16.7 ± 1.6 
15.7 ± 1.2 
15.8 ± 1.3 
20.0 ± 1.9 
20.6 ± 1.5 
NR 
NR 
- 
DSM-IV Medication-free IFN-γ, IL-
1β, IL-2, IL-
5, IL-10, 
TNF-α 
Serum - ELISA 
Brambilla et 
al. 
Italy 
1998 Cross-sectional 
& 
longitudinal 
Female AN-R 
Female AN-BP 
Female BN 
Female HC 
9 
17 
24 
26 
25.0 ± 8.8 
23.3 ± 4.7 
23.6 ± 4.4 
24.1 ± 3.2 
14.8 ± 1.8 
17.3 ± 1.8 
22.8 ± 2.5 
21.7 ± 1.2 
6.7 ± 8.5  
6.2 ± 3.8  
4.2 ± 3.2  
- 
 
DSM-IV Medication-free IL-1β, IL-6, 
TNF-α 
 
Plasma - 
immunoradiometric 
assays 
Brambilla et 
al. 
Italy 
2001 Cross-sectional Female AN-R 
Female AN-BP 
Female HC 
9 
5 
13 
24.5 ± 6.4 
19.2 ± 3.1 
26.1 ± 1.9 
13.4 ± 1.2 
14.9 ± 2.3 
20.9 ± 1.7 
6.2 ± 4.7 
2.6 ± 1.8 
- 
DSM-IV Medication-free IL-1β, IL-6, 
TNF-α, 
 
Plasma - 
radioimmunoassay 
Corcos et al. 
France 
2001 Cross-sectional Female AN 
Female HC 
29 
20 
20.1 ± 10.2 
23.7 ± 12.1 
NR 
NR 
NR 
- 
DSM-IV NR IFN-γ, IL-1, 
IL-2, IL-4, 
IL-6, IL-10, 
TGF-β, 
TNF-α 
Serum - ELISA 
sandwich-type 
Dolezalova 
et al. 
Czech 
Republic 
2007 Cross-sectional Female AN 
Female HC 
12 
18 
NR 
NR 
16.37 ± 1.4 
22.96 ± 2.8 
NR 
- 
DSM-IV Medication-free IL-6 Serum - human serum 
adipokine LINCOplex 
kit 
Jiskra et al. 
Czech 
Republic 
2000 Cross-sectional Female AN-R 
Female HC 
16 
16 
NR 
NR 
15.0 ± 2.3 
22.2 ± 2.5 
NR 
- 
DSM-IV NR TNF-α Serum - ELISA 
Karczewska-
Kupczewska 
et al. 
Poland 
2012 Cross-sectional Female AN-R 
Female HC 
20 
28 
22.3 ± 4.6 
25.3 ± 4.9 
15.7 ± 1.5 
21.3 ± 1.9 
1.4 ± 1.0  
- 
DSM-IV Medication-free TNF-α Serum - immunoassay 
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Karczewska-
Kupczewska 
et al. 
Poland 
2013 Cross-sectional Female AN-R 
Female HC 
19 
27 
22.0 ± 4.8 
23.5 ± 3.6 
15.9 ± 1.2 
22.0 ± 1.9 
NR 
- 
DSM-IV Medication-free IL-6 Serum - 
immunoenzymatic 
method 
Krizova et 
al. 
Czech 
Republic 
2002 Cross-sectional 
& 
longitudinal 
Female AN-R 
Female HC 
15 
15 
NR 
NR 
14.1 ± 6.2 
22.5 ± 9.7 
NR 
- 
DSM-IV NR TNF- α Serum - ELISA 
Krizova et 
al. 
Czech 
Republic 
2008 Cross-sectional Female AN 
Female HC 
28 
38 
NR 
NR 
15.7 ± 1.9 
22.3 ± 2.5 
NR 
- 
DSM-IV NR TNF-α Serum - ELISA 
Misra et al. 
United States 
of America 
2006 Cross-sectional 
& 
longitudinal 
Female AN-R 
Female HC 
23 
20 
16.2 ± 1.6 
15.4 ± 1.8 
16.7 ± 1.2 
21.9 ± 3.6 
0.7 ± 0.9 
- 
DSM-IV NR IL-6 Serum - high-
sensitivity sandwich 
enzyme immunoassay 
Nagata et al. 
Japan 
2006 Cross-sectional 
& 
longitudinal 
Female BN 
Female HC 
20 
14 
23.1 ± 3.9 
24.9 ± 3.5 
19.7 ± 2.6 
19.8 ± 0.8 
NR 
- 
DSM-IV Medication-free IL-6 Plasma - ELISA 
Nakai et al. 
Japan 
1999 Cross-sectional 
& 
longitudinal 
Female AN 
Female HC 
20 
20 
22.1 ± 4.5 
20.2 ± 1.3 
13.7 ± 1.8 
19.9 ± 0.9 
3.8 ± 3.6 
- 
DSM-IV Medication-free TNF-α Plasma - enzyme 
immunoassay 
Nakai et al. 
Japan 
2000 Cross-sectional Female BN 
Female HC 
20 
20 
NR 
NR 
NR 
NR 
NR 
- 
DSM-IV Medication-free TNF-α Plasma - enzyme 
immunoassay 
Nogueira et 
al. 
France 
2010 Cross-sectional Female AN-R 
Female AN-BP 
Female HC 
15 
9 
14 
21.1 ± 4.8 
25.4 ± 6.9 
24.0 ± 2.1 
13.3 ± 1.3 
13.8 ± 0.9 
20.4 ± 1.8 
NR 
NR 
- 
DSM-IV n=12 medication-
free; n=10 
antidepressants, 
neuroleptics 
and/or anxiolytics  
IL-1β, TNF-
α 
Plasma - ELISA 
Ostrowska et 
al. 
Poland 
2015 Cross-sectional Female AN 
Female HC 
59 
17 
15.3 ± 1.6 
15.7 ± 1.7 
15.3 ± 1.8 
20.4 ± 2.2 
NR 
- 
DSM-IV NR IL-1β, IL-6, 
TNF-α 
Serum - high-
sensitivity human 
ELISA 
Ostrowska et 
al. 
Poland 
2016 Cross-sectional Female AN-R 
Female HC 
60 
20 
15.3 ± 1.6 
15.7 ± 1.7 
15.3 ± 1.8 
20.4 ± 2.2 
1.0 ± NR DSM-IV NR TGF-β Serum - ELISA 
Pomeroy et 
al. 
United States 
of America 
1994 Cross-sectional 
& 
longitudinal 
Female AN 
Female HC 
16 
11 
23.3 ± 2.0 
27.7 ± 6.6 
NR 
NR 
NR 
- 
DSM-III Medication-free IL-6, TGF-β, 
TNF-α 
Serum - ELISA (TNF-
α) & bioassay (IL-6) 
Shimizu et 
al. 
Japan 
2005 Cross-sectional 
& 
longitudinal 
Female AN-R 
Female HC 
12 
12 
13.9 ± 1.1 
13.7 ± 1.1 
13.9 ± 2.1 
17.7 ± 2.0 
NR 
- 
DSM-IV Medication-free TNF-α Plasma - ELISA 
Terra et al. 
Spain 
2013 Cross-sectional Female AN-R 
Female HC 
28 
33 
27.4 ± 1.4 
32.6 ± 1.3 
16.8 ± 0.2 
21.8 ± 0.3 
8.3 ± 1.4 DSM-IV NR IL-6 Plasma - ELISA 
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Vaisman et 
al. 
Israel 
2004 Cross-sectional 
& 
longitudinal 
Female AN 
Female HC 
7 
7 
NR 
NR 
NR 
NR 
NR 
- 
DSM-IV NR IL-1β, IL-3, 
IL-6, TNF-α 
Serum - solid phase 
ELISA 
Victor et al. 
Spain 
2015 Cross-sectional Female AN 
Female HC 
24 
36 
22.4 ± 6.8 
24.3 ± 3.4 
16.3 ± 1.6 
20.9 ± 1.4 
NR 
- 
DSM-IV NR IL-6, TNF-α Serum - Luminex 200 
flow analyser device 
Yasuhara et 
al. 
Japan 
2007 Cross-sectional 
& 
longitudinal 
Female AN-R 
Female HC 
7 
11 
23.2 ±7.8 
23.0 ± 2.2 
13.6 ± 1.8 
19.8 ± 1.8 
3.9 ± 4.2 
- 
DSM-IV NR IL-1β, IL-6, 
TNF-α 
Serum - high 
sensitivity assay 
N= number; SD = standard deviation; BMI = body mass index; ED = eating disorder; AN = anorexia nervosa; HC = healthy control; NR = not reported; BN = bulimia 
nervosa; AN-R = anorexia nervosa restricting subtype; AN-BP = anorexia nervosa binge-purge subtype; DSM = Diagnostic and Statistical Manual of Mental Disorders; 
ELISA = enzyme-linked immunosorbent assay; TNF = tumor necrosis factor; IL = interleukin; TGF = transforming growth factor; IFN = interferon 
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Table 2. Summary of comparative outcomes and heterogeneity for all conducted meta-analyses. 
 
TNF-α = tumor necrosis factor-alpha; IL-1β = interleukin-1 beta; IL-6 = interleukin-6; TGF-β = transforming growth factor-beta; N = number; ED = eating 
disorder; HC = healthy control; SMD = standardised mean difference; CI = confidence intervals; Z = z score; p = p value; df = degrees of freedom; AN = 
anorexia nervosa; AN-R = anorexia nervosa restrictive subtype; AN-BP = anorexia nervosa binge-purge subtype; BN = bulimia nervosa. 
 
 
 TNF-α  IL-1β  IL-6  TGF-β 
Group 
 N 
(ED, 
HC) 
SMD 95% CI Z p Heterogeneity  
N 
(ED, 
HC) 
SMD 95% CI Z p Heterogeneity  
N 
(ED, 
HC) 
SMD 95% CI Z p Heterogeneity  
N 
(ED, 
HC) 
SMD 95% CI Z p 
Heterogeneity 
All EDs 
combined 
 798 
(454, 
344) 
0.56 0.17, 
0.94 
2.80 0.005 I2 = 84.2%;  
Χ2 = 107.79;  
df = 17; p<0.00 
 307  
(205, 
102) 
0.77 -0.13, 
1.66 
1.68 0.093 I2 = 90.8%;  
Χ2 = 65.22;  
df = 6; p<0.00 
 589 
(331, 
258) 
0.53 0.19, 
0.87 
3.08 0.002 I2 = 72.9%;  
Χ2 = 44.34;  
df = 12; p<0.00 
 156 
(105, 
51) 
-0.59 -2.37, 
1.20 
0.65 0.518 I2 = 95.3%;  
Χ2 = 42.29;  
df = 2; p<0.00 
                             
AN  704 
(380, 
324) 
0.48 0.09, 
0.87 
2.43 0.015 I2 = 82.8%;  
Χ2 = 92.96;  
df = 16; p<0.00 
 264  
(162, 
102) 
0.78 -0.17, 
1.72 
1.61 0.110 I2 = 91.0%;  
Χ2 = 66.46;  
df = 6; p<0.00 
 520 
(276, 
244) 
0.59 0.24, 
0.94 
3.31 0.001 I2 = 71.6%;  
Χ2 = 38.78;  
df = 11; p<0.00 
 156 
(45, 
31) 
-0.59 -2.37, 
1.20 
0.65 0.518 I2 = 95.3%;  
Χ2 = 42.29;  
df = 2; p<0.00 
AN-R  242 
(107, 
135) 
0.12 -0.04, 
0.44 
0.72 0.470 I2 = 31.9%;  
Χ2 = 10.27;  
df = 7; p=0.174 
 108 
(44, 
64) 
0.49 0.08, 
0.89 
2.37 0.018 I2 = 0.0%;  
Χ2 = 0.50;  
df = 3; p=0.919 
 229 
(99, 
130) 
0.36 -0.07, 
0.78 
1.62 0.105 I2 = 57.8%;  
Χ2 = 111.84;  
df = 5; p=0.037 
 
- - - - - - 
AN-BP  84 
(31, 
84) 
-0.50 -1.31, 
0.30 
1.22 0.221 I2 = 63.4%;  
Χ2 = 5.32;  
df = 2; p=0.070 
 
 84 
(31, 
84) 
1.13 -0.30, 
2.57 
1.55 0.122 I2 = 85.4%;  
Χ2 = 13.74;  
df = 2; p=0.001 
 
- - - - - - 
 
- - - - - - 
                
      
 
      
BN  107  
(55, 
52) 
0.90 -0.26, 
2.06 
1.52 0.130 I2 = 87.2%;  
Χ2 = 15.67;  
df = 2; p<0.00 
 
- - - - - - 
 107 
(55, 
52) 
0.13 -0.49, 
0.76 
0.42 0.67 I2 = 58.8%;  
Χ2 = 4.86; 
df = 2; p=0.088 
 
- - - - - - 
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Table 3. Results of the conducted meta-regressions. 
 Covariate N included 
studies 
Coefficient L 95% 
CI 
U 95% 
CI 
p 
Eating disorders studies 
TNF-α Age 11 -0.083 -0.284 0.119 0.373 
 BMI  0.003 -0.384 0.390 0.986 
IL-1β Age 6 -0.279 -0.712 0.154 0.132 
 BMI  -0.053 -0.683 0.576 0.805 
IL-6  Age 9 -0.132 -0.215 -0.049 0.008 
 BMI  -0.106 -0.267 0.055 0.157 
 
Anorexia nervosa studies 
TNF-α Age 11 -0.080 -0.274 0.114 0.369 
 BMI  0.204 -0.434 0.842 0.482 
IL-1β Age 6 -0.301 -0.701 0.098 0.096 
 BMI  -0.017 -1.189 1.15 0.966 
IL-6 Age 8 -0.135 -0.230 -0.039 0.015 
 BMI  -0.109 -0.460 0.242 0.461 
*Significant findings at p<0.05 highlighted in bold. 
N = number; L = lower; U = upper; CI = confidence interval, p = p value; TNF-α = tumor necrosis 
factor-alpha; IL-1β = interleukin-1 beta; IL-6 = interleukin-6; BMI = body mass index 
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Records identified through database 
searching 
(n = 1052) 
 
- Web of Science n = 485 
- MEDLINE n = 469 
- PubMed n = 98 
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Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 726) 
Records screened 
(n = 726) 
Records excluded 
(n = 658) 
Full-text articles assessed 
for eligibility 
(n = 68) 
Full-text articles excluded, 
with reasons 
(n = 32) 
 
- No cytokine 
measurement (n = 12) 
- Cytokine production  
or genetic expression 
assessed (n = 18) 
- No current DSM  or 
ICD diagnosed eating 
disorder (n = 1) 
- No comparison group 
or longitudinal 
assessment of cytokine 
concentration (n=1) 
 
Studies included in 
qualitative synthesis 
(n = 36) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 25) 
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